URISPAS Drug Patent Profile
Which patents cover Urispas, and when can generic versions of Urispas launch?
Urispas is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.
The generic ingredient in URISPAS is flavoxate hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the flavoxate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Urispas
A generic version of URISPAS was approved as flavoxate hydrochloride by PADAGIS US on December 16th, 2004.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for URISPAS?
- What are the global sales for URISPAS?
- What is Average Wholesale Price for URISPAS?
Summary for URISPAS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 85 |
| Clinical Trials: | 2 |
| DailyMed Link: | URISPAS at DailyMed |
Recent Clinical Trials for URISPAS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mahidol University | Phase 4 |
| Paddock Laboratories, Inc. | Phase 1 |
| Padagis LLC | Phase 1 |
US Patents and Regulatory Information for URISPAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ortho Mcneil Janssen | URISPAS | flavoxate hydrochloride | TABLET;ORAL | 016769-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
